Induced Pluripotent Stem Cells Production Market Size [2031]

Report Description

Induced Pluripotent Stem Cells Production Market Outlook 2031

The global induced pluripotent stem cells production market size was USD 1.47 Billion in 2022 and is likely to reach USD 2.76 Billion by 2031, expanding at a CAGR of 9.3% during 2023–2031. The market growth is further attributed to the high demand for drug discovery and toxicity testing.

Rising demand for drug discovery and toxicity testing is anticipated to drive the induced pluripotent stem cells (iPSCs) production market. iPSCs are derived from adult cells and are reprogrammed to an embryonic-like state, which allows them to differentiate into any cell type in the body. iPSCs are used to create disease models that help researchers understand the molecular basis of diseases and develop drugs. They are also used to identify novel drug targets and to screen compounds for toxicity.

• In July 2022, Curi Bio launched the Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis. It allows for the discovery of therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles of healthy and disease models.

Get Free Sample Report

The market report finds that the COVID-19 pandemic fueled the induced pluripotent stent cells (iPSCs) production market, due to the increasing demand for iPSCs-based research & development. The continuous strive by scientists to develop novel treatments and therapies to manage the SARS CoV-2 infection drives the demand for iPSCs as research tools. iPSC creates organ models that are physiologically identical to real organs and are utilized to study the pathophysiology of viral infection in humans.

Impact of Artificial Intelligence in Induced Pluripotent Stent Cells Production Market

Artificial Intelligence (AI) technologies are expected to boost the induced pluripotent stent cells production market during the forecast period. AI is used to improve the quality and safety of induced pluripotent stem cell products. The ability to validate cells and functions at different stages of the iPSC manufacturing process is crucial for producing therapeutic cells and organs on demand.

AI-based methods are proving helpful for these complex tasks and revolutionize the way iPSCs are managed to create surrogate cells and organs. The use of iPSC holds great potential for the development of personalized therapies without the ethical issues associated with embryonic stem cell treatment and the immunological risk of rejection.

Induced Pluripotent Stem Cells Production Market Dynamics

Get Free Sample Report

Major Drivers

Increasing therapeutic applications is expected to fuel the induced pluripotent stem cells production market in the coming years. iPSCs are used in various applications, including disease modeling, drug discovery, and regenerative medicine. iPSCs are a type of immature cell that is generated from adult cells and have the ability to differentiate into any type of cell in the body.

In terms of therapeutic applications, iPSCs are used to treat a variety of diseases, including Parkinson's disease, spinal cord injury, and heart disease. iPSCs are used to generate patient-specific cells for transportation, which helps avoid immune rejection. They are also used to model diseases and test new drugs.

Existing Restraints

High cost of iPSC production is expected to hinder the market. iPSC production costs are influenced by a combination of technological challenges, quality requirements, and the need for skilled personnel. iPSCs require specialized culture methods for their stable mass production. These methods are still in the early development stages, leading to challenges in scaling up production.

Emerging Opportunities

Technological advancements in reprogramming techniques is expected to create lucrative opportunities for the market players. Reprogramming procedures include induced pluripotent stem cells, somatic cell nuclear transfer, and direct reprogramming of specific cell lineages, which have the capability to modify cell plasticity in translational drugs for cancer treatment.

The cells are then reprogrammed into iPSCs by nonviral or viral-mediated gene allocation before the replacement of the disease-causing genes with healthy genes. Genetically modified iPSCs are enriched and then differentiated into the affected cell subtype. The cells are then reinfused into the patient.

• In February 2022, EdiGene, Inc. collaborated with Neukio Biotherapeutics to develop next-generation immune cell therapies. This collaboration leverages EdiGene’s expertise in high throughput genome editing screening and Neukio’s strength in the development and manufacture of iPSC and natural killer cells. 

Scope of Induced Pluripotent Stem Cells Production Market Report

The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Induced Pluripotent Stem Cells Production Market Segment Insights

Product Segment Analysis

Based on product, the induced pluripotent stem cells production market is divided into automated platforms, instruments/devices, consumables & kits, and services.

The consumables & kits segment is further divided into kits, media, and others. The consumables & kits segment is projected to expand at a significant pace during the projection period, owing to the increasing research & development activities in induced pluripotent stem cells (iPSCs). Several key players enable end-users to use iPSC kits such as generation kits, reprogramming kits, and differentiation kits, which is expected to boost the segment.

Advancements in iPSC technology have increased the development of specific consumables & kits, which made it easy for researchers to work with iPSCs. This, in turn, is likely to boost the consumables & kits segment in the market.

The automated platforms segment is anticipated to hold a key share of the market in the coming years, due to the regulatory level of quality control and high demand for stem cell products. Automated platforms provide reproducible & reliable results, well-maintained conditions of manufacturing, reduced labor dependence, and standardization of protocols while eliminating human biases, which is expected to boost the segment in the market.

Application Segment Analysis

In terms of application, the global market is segregated into regenerative medicine, drug development & discovery, toxicology studies, and others. The drug development & discovery segment is projected to account for a major market share in the coming years, owing to the rising importance of iPSC in the field of drug development & discovery.

The use of iPSC-derived neurons advances compound screening and evaluation of drug efficacy. These cells contain the genetic background of patients to accurately model disease-specific pathophysiology and phenotype. iPSCs have many applications in the fields of gene therapy, disease modeling, and drug discovery. The somatic cells of patients are used for the generation of iPSCs and further utilized for studying the diseases.

Diseased iPSCs are repaired by gene therapy and used for the generation of healthy somatic cells to transplant into the patient, or they are used to produce somatic cells for disease modeling or drug screening.

The regenerative medicine segment is anticipated to expand at a considerable CAGR during the forecast period, due to the immense applications and robust product pipelines by major companies. iPSCs-derived organoids and organs are analyzed for both regenerative therapy and disease modeling. In regenerative medicine, injured or deteriorated tissues are fixed by the generation of those tissues with the help of iPSCs in labs and transplanting them to the site of injury or deterioration.

Get Free Sample Report

Process Segment Analysis

On the basis of process, the induced pluripotent stem cells production market is segmented into automated and manual. The manual segment is expected to register robust growth during the forecast period. Manual iPSCs are generated by introducing reprogramming factors into somatic cells using non-viral methods.

The process of generating manual iPSCs is similar to that of iPSCs, as it is done manually without the use of viral vectors. This method is considered safer and more efficient than the traditional viral vector-based methods.

Workflow Segment Analysis

Based on workflow, the global market is segmented into cell culture, engineering, cell characterization/analysis, and others. The cell culture segment is projected to hold a key share of the market in the coming years, owing to the continuous investments by key players. Cell culture workflow includes revenue generated from iPSC harvest products, differentiation products, and expansion products, which is expected to boost the segment in the market.

The cell characterization/analysis segment is expected to register robust growth during the forecast period, due to the increasing use of assays that are based on cells in drug discovery. The segment growth is further attributed to the growing incidence of chronic diseases such as cancer, which increases the use of cell-based assays for treatment and detection.

Get Free Sample Report

End-user Segment Analysis

On the basis of end-user, the global induced pluripotent stem cells production market is segmented into hospitals & clinics, research & academic institutes, and biotechnology & pharmaceutical companies.

The biotechnology & pharmaceutical companies segment is anticipated to hold a key share of the market in the coming years, owing to the increasing adoption of several consumable & kits and instruments as well as iPSC products. Biotechnology & pharmaceutical companies are continuously launching products, which is expected to boost the market.

Regional Analysis

In terms of region, the global induced pluripotent stem cells production market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the increasing prevalence of chronic diseases, rising number of strategic business models, and developed healthcare infrastructure.

The regional market growth is further attributed to the increasing research and development activities, rising number of clinical trials for iPSCs, and the availability of advanced dissolution testing equipment and technology.

The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, owing to the increasing awareness of the potential of personalized treatments and growing economies. The regional market growth is further attributed to the intensive low-cost driven stem cell-based research and betterment in healthcare plans. Several companies are collaborating to launch products and services, which is expected to boost the market. For instance,

• In June 2023, REPROCELL Inc collaborated with IBM and STFC Hartree Centre successfully launched a commercial service called as Pharmacology AI platform. This new pharmacology AI platform is unique in its ability to quickly reveal the genomic or clinical features driving drug response.

  Get Free Sample Report